Navigation Links
Neurocrine Announces Work Force Restructuring
Date:5/5/2009

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today staff reductions of approximately 60 employees, as a part of its restructuring program to focus the Company's efforts on its clinical programs and pre-clinical development leads. Following these reductions, Neurocrine will have approximately 60 employees.

"We are disappointed that we have to make this painful decision that will have such an effect on so many of our employees and their families. Our employees have always shown the highest level of commitment and displayed incredible passion for the efforts around drug discovery; however, in order to meet our clinical goals, we have to refocus our resources. I want to sincerely thank the departing employees for their efforts and loyalty, these are highly talented people and I am sure they are going to find continued success in their careers," said Kevin C. Gorman President & CEO. "We will maintain our efforts on elagolix, move our VMAT2 program into the clinic, and focus on the other high value assets. We continue to conservatively manage our cash resources while advancing our pipeline."

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
4. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
5. Neurocrine Biosciences Reports Third Quarter 2008 Results
6. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
7. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
9. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
10. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
11. Neurocrine Biosciences Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):